TECHNICAL DATA SHEET

CyFlow™ CD263 FITC

Anti-Hu; Clone TRAIL-R3-02

REF **CK054023**

For Research Use Only.

Not for use in diagnostic or therapeutic procedures.

Specifications

Antigen	CD263
Alternative Names	TRAILR3, DCR1, LIT, TRID, TNFRSF10c
Clone	TRAIL-R3-02
Clonality	monoclonal
Format	FITC
Host / Isotype	Mouse / IgG1
Species Reactivity	Human
Negative Species Reactivity	—
Quantity [Concentration]	0.1 mg [0.1 mg/ml]
Immunogen	TRAIL-R3 (aa 1-280) - hIgGhc fusion protein

Specificity

The mouse monoclonal antibody TRAIL-R3-02 recognizes CD263 (TRAIL-R3) antigen, a 35 kDa GPI-anchored extracellular membrane protein expressed mainly on neutrophils.

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

Application

The reagent is designed for Flow Cytometry analysis. Suggested working usage is 3 µg/ml. Indicated dilution is recommended starting point for use of this product, but working concentrations should be validated by the investigator.

Other usages may be determined from the scientific literature.

Storage Buffer

The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.1% (w/v) sodium azide.

Storage and Stability

Storage	Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
Stability	Do not use after expiration date stamped on vial label.

Background Information

CD263 (TRAIL-R3, TR3, DcR1, LIT, TRID), expressed mainly on neutrophils, belongs to receptors of TRAIL, a TNF-like membrane cytotoxic protein that induces apoptosis in many tumor cells, but not in normal cells. TRAIL-R3, however, is a GPI-anchored protein that lacks cytoplasmic death domain, thus it is unable to induce apoptosis and serves as a negative regulator of apoptotic signaling by competing for binding of TRAIL with death receptor 5 (DR5).

References

- Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK: Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA. 2005 Dec 13; 102(50):18099-104. < PMID: 16319225 >
- Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S: Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer. 2005 May 25; 5(1):54. < PMID: 18518976 >
- Mérino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006 Oct; 26(19):7046-55. < PMID: 16980609 >

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

- Deligezer U, Dalay N: Expression of the TRAIL Receptors in Blood Mononuclear Cells in Leukemia. Pathol Oncol Res. 2007; 13(4):290-4. < PMID: 18158563 >
- Falschlehner C, Emmerich CH, Gerlach B, Walczak H: TRAIL signalling. Int J Biochem Cell Biol. 2007; 39(7-8):1462-75. < PMID: 17403612 >

The Safety Data Sheet for this product is available at www.sysmex-partec.com/services.

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com